SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-24-094340
Filing Date
2024-11-05
Accepted
2024-11-05 08:00:30
Documents
4
Period of Report
2024-11-05

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0219853-6k_nlspharma.htm 6-K 43331
2 AGREEMENT AND PLAN OF MERGER, DATED NOVEMBER 4, 2024, BY AND BETWEEN NLS PHARMAC ea021985301ex99-1_nlspharma.htm EX-99.1 580302
3 FORM OF CONTINGENT VALUE RIGHT AGREEMENT, BY AND BETWEEN NLS PHARMACEUTICS LTD. ea021985301ex99-2_nlspharma.htm EX-99.2 104169
4 FORM OF SUPPORT AGREEMENT BY AND BETWEEN NLS PHARMACEUTICS LTD. AND EACH OF THE ea021985301ex99-3_nlspharma.htm EX-99.3 47685
  Complete submission text file 0001213900-24-094340.txt   776531
Mailing Address THE CIRCLE 6 8058 ZURICH V8 CH-6370
Business Address THE CIRCLE 6 8058 ZURICH V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

IRS No.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 241425704
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)